Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.verified

CPRX

Price:

$20.43

Market Cap:

$2.42B

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; a...[Read more]

Industry

Biotechnology

IPO Date

2006-11-08

Stock Exchange

NASDAQ

Ticker

CPRX

The Enterprise Value as of September 2024 (TTM) for Catalyst Pharmaceuticals, Inc. (CPRX) is 2.05B

According to Catalyst Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.05B. This represents a change of 41.28% compared to the average of 1.45B of the last 4 quarters.

Catalyst Pharmaceuticals, Inc. (CPRX) Historical Enterprise Value (quarterly & annually)

How has CPRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Catalyst Pharmaceuticals, Inc. over the last ten years is 520.87M. The current 2.05B Enterprise Value has changed 39.31% with respect to the historical average. Over the past ten years (40 quarters), CPRX's Enterprise Value was at its highest in in the December 2023 quarter at 1.66B. The Enterprise Value was at its lowest in in the June 2016 quarter at 40.12M.

Quarterly (TTM)
Annual

Average

520.87M

Median

246.76M

Minimum

73.13M

Maximum

1.65B

Catalyst Pharmaceuticals, Inc. (CPRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Catalyst Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 280.15%

Maximum Annual Enterprise Value = 1.65B

Minimum Annual Increase = -56.95%

Minimum Annual Enterprise Value = 73.13M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.65B1.49%
20221.63B205.88%
2021532.33M146.99%
2020215.52M-27.48%
2019297.18M64.64%
2018180.50M-35.07%
2017277.99M280.15%
201673.13M-56.95%
2015169.87M-6.36%
2014181.41M109.92%

Catalyst Pharmaceuticals, Inc. (CPRX) Average Enterprise Value

How has CPRX Enterprise Value performed in the past?

The current Enterprise Value of Catalyst Pharmaceuticals, Inc. (CPRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

1.27B

5-year avg

865.16M

10-year avg

520.87M

Catalyst Pharmaceuticals, Inc. (CPRX) Enterprise Value vs. Peers

How is CPRX’s Enterprise Value compared to its peers?

Catalyst Pharmaceuticals, Inc.’s Enterprise Value is greater than Day One Biopharmaceuticals, Inc. (970.79M), greater than Terns Pharmaceuticals, Inc. (770.84M), greater than X4 Pharmaceuticals, Inc. (49.50M), greater than Inozyme Pharma, Inc. (395.96M), greater than Mereo BioPharma Group plc (657.97M), less than Exelixis, Inc. (7.69B), less than TG Therapeutics, Inc. (3.94B), less than Viking Therapeutics, Inc. (7.10B), less than Madrigal Pharmaceuticals, Inc. (4.68B), greater than BioXcel Therapeutics, Inc. (73.31M), less than Axsome Therapeutics, Inc. (4.27B), less than Incyte Corporation (11.60B), less than ImmunoGen, Inc. (8.19B), less than Sarepta Therapeutics, Inc. (12.91B), less than ACADIA Pharmaceuticals Inc. (2.59B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Hepion Pharmaceuticals, Inc. (1.95M), greater than Akero Therapeutics, Inc. (1.60B), less than Reata Pharmaceuticals, Inc. (6.68B),

Build a custom stock screener for Catalyst Pharmaceuticals, Inc. (CPRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Catalyst Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Catalyst Pharmaceuticals, Inc. (CPRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Catalyst Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Catalyst Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?

What is the 3-year average Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?

What is the 5-year average Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX)?

How does the current Enterprise Value for Catalyst Pharmaceuticals, Inc. (CPRX) compare to its historical average?